Despite a turbulent reporting season impacted by heightened volatility driven by rising uncertainty, Portfolio Manager Joel Fleming continues to find pockets of value in the Australian microcaps market.

Joel catches up with ausbiz’s Andrew Geoghegan to chat through the outlook for his investment universe, flagging that when you focus on the fundamentals Australian small companies look undervalued.

Andrew and Joel talk through three opportunities for the period ahead: two companies within the mining sector underpinned by strong management teams and favourable commodity outlooks, and one biotech stock working through phase three trials for its product treating a rare kidney disease.